ArticleFrontiers in oncology2026
AQP4-IgG-positive myelitis occurring in a patient with small cell lung cancer: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myelopathy in patients with small cell lung cancer (SCLC) is often attributed to metastatic spinal cord involvement. However, non-compressive inflammatory conditions, particularly aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD), can produce similar clinical and radiologic features, creating substantial diagnostic uncertainty. Case presentation: A male aged 65 years with extensive-stage SCLC presented with acute urinary retention followed by rapidly progressive paraplegia. Spinal magnetic resonance imaging (MRI) revealed longitudinally extensive intramedullary T2-hyperintense lesions affecting the cervical and thoracic spinal cord, with patchy contrast enhancement and no evidence of vertebral destruction, epidural mass, or spinal cord compression. Cerebrospinal fluid (CSF) examination demonstrated inflammatory abnormalities without malignant cells, and infectious causes were excluded. Serum and CSF testing were strongly positive for AQP4-IgG, establishing a diagnosis of AQP4-IgG-positive NMOSD. The patient received high-dose intravenous methylprednisolone followed by adjunctive intravenous immunoglobulin (IVIG). Plasma exchange was not performed because of advanced malignancy and concerns regarding procedural risks. Satralizumab was initiated during corticosteroid tapering for maintenance immunotherapy. Neurological function subsequently stabilized, and partial recovery of independence in activities of daily living was achieved. Conclusions: This case highlights that AQP4-IgG-positive myelitis can occur in patients with SCLC. In patients presenting with non-compressive longitudinally extensive transverse myelitis (LETM), particularly when imaging shows no evidence of compression and CSF cytology is negative for malignant cells, prompt AQP4-IgG testing is critical to prevent misdiagnosis and enable early initiation of appropriate immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.